Technologies and Platforms for Biomedical Systems by De Micheli, Giovanni
Technologies and Platforms 
for Biomedical Systems 
Giovanni	  De	  Micheli	  
Outline 
▲ Introduc3on	  
▲ Electronic	  implants:	  a	  lab	  under	  the	  skin	  




▲ Relentless	  growth	  of	  compu7ng,	  storage	  and	  
communica7on	  technologies	  
▽ Inexpensive	  terminals	  providing	  ubiquitous	  services	  
▲ Biomedical	  science	  becoming	  more	  quan7ta7ve	  
▽ Societal	  need	  of	  beCer	  care	  at	  lower	  costs	  
▲ Big	  data	  issues	  fueling	  research	  and	  businesses	  











The sensory interface 
▲ The	  More	  than	  Moore	  revolu7on	  
[Courtesy:	  ST]	   [Courtesy:	  Carrara	  EPFL]	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What is health? 
State of complex physical, mental and social well-being 



















▲ BeCering	  medicine	  with	  electronic	  means	  
▲ Bringing	  low-­‐cost	  medicine	  to	  the	  people	  
▲ Exploi7ng	  electronic	  well-­‐being	  as	  a	  lifestyle	  
▲ Opportuni7es	  
▽ Synergy	  of	  integrated	  electronic	  and	  sensing	  
▽ PlaQorm-­‐based	  design	  of	  sensors	  




▲ Electronic	  implants:	  a	  lab	  under	  the	  skin	  
▽ Biosensing	  technology	  
▽ PlaKorm-­‐based	  design	  
▽ Low-­‐power	  and	  energy	  
▲ Drug	  monitoring	  and	  administra7on	  
▲ Conclusions	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Monitoring chronic patients 
▲ Con7nuous	  real-­‐7me	  monitoring	  
▲ Current	  devices	  are	  external	  and	  limited	  
to	  a	  single	  measurement	  
▲ Wireless,	  baCeryless	  implant	  
▲ Tracking	  mul7ple	  metabolites	  
▲ Driver	  technology	  for	  a	  wide	  	  
set	  of	  applica7ons	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Case study: implant 
20	  x	  4.2	  x	  3	  mm	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Case study: external patch 
FEATURES	  
Remote	  powering	  through	  induc7ve	  link	  
Short-­‐range	  bidirec7onal	  communica7on	  
Long-­‐range	  comm.	  with	  remote	  devices	  
ADVANTAGES	  
Improved	  wearability	  




       Android user interface 
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Target	  molecule	  detec3on	  
CARBON NANOTUBES 
CNTs + PROBE ENZYMES 
The sensing technology 
The electrochemical sensing principle 
I 
V	  
 	  Peak	  posi7on	  returns	  the	  type	  of	  chemical	  contained	  into	  the	  sample	  (target	  signature)	  
 	  Peak	  current	  returns	  the	  concentra7on	  of	  the	  target	  
 	  Diﬀerent	  isoforms	  of	  the	  cytochrome	  P450	  enable	  detec7on	  of	  diﬀerent	  targets	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The platform and its components 
▲ Speciﬁc	  components	  
▽ Probes	  and	  electrodes	  
▽ Chambers	  and	  ﬂuidic	  circuits	  
▲ Electronic	  components	  
▽ Transconductance	  ampliﬁer	  and	  data	  conversion	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!
Layout	  of	  the	  fabricated	  IC	  
(0.18um	  technology)	  
▲ A	  biosensing	  plaKorm	  
▲ Small	  size,	  low	  power	  
▲ Remotely	  powered	  
▲ Flexible	  and	  programmable	  
▲ High	  accuracy	  
18	  
▲ Implants	  must	  last	  long	  7me	  without	  interven7on	  
▽ BaCery	  replacement	  
▽ BaCery	  toxicity	  
▲ Dissipated	  heat	  must	  be	  minimal	  
▽ Par7cularly	  cri7cal	  for	  brain	  implants	  
▲ Slow	  signal	  –	  low	  noise	  solu7ons	  
Low power/energy is key 
19	  
Powering by inductive link 
 	  Wireless power transfer through inductive link 
 	  Bidirectional data communication 
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Multi-layer receiving inductors 
  Higher link efficiency (up to 35% higher) 
  Higher voltage gain (up to one order of                           
magnitude higher) 
21	  
Power and data transmission 




▲ Co-­‐design	  of	  electronics	  and	  sensing	  is	  key	  
▽ Achieve	  low-­‐power	  consump7on	  
▽ Achieve	  small	  footprint	  
▲ Electronic	  technology	  can	  be	  extended	  upwards	  
▽ Monolithic	  integra7on	  
▽ Silicon	  interposer	  technologies	  
▲ PlaQorm-­‐based	  design	  





▲ Electronic	  implants:	  a	  lab	  under	  the	  skin	  
▲ Drug	  monitoring	  and	  administra3on	  
▽ Real-­‐3me	  measurements	  in	  pa3ents	  and	  lab	  animals	  
▽ Machine	  learning	  predic3on	  methods	  




What does this mean in practice? 
26	  
INDUCTIVE LINK 
Monitoring drugs in lab animals	  
EXTERNAL UNIT 
Kilinc, Enver G., et al. /  New Circuits and Systems Conference, 2013 IEEE 11th International. IEEE, 2013. 27	  
3-Dimensional integrated sensor 
SENSING PLATFORM 
INTEGRATED CIRCUITS 
COIL FOR POWER AND 
DATA TRANSMISSION 
28	  
Operation and measurements 
WE 
RE CE 
4 Independent cells 
(3-electrodes) 
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         MTX 200 µM 
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▲  TDM	  measures	  the	  real	  concentra7on	  values	  to	  es7mate	  clinical	  
parameters	  
▲  An	  a	  posteriori	  adapta7on	  for	  pa7ents’	  parameters	  




▲ Intravenous	  bolus	  dose	  
▽ One-­‐compartment	  model	  
Pharmacokinetic models 
C:	  concentra/on	  value	  
V:	  body	  volume	  
Kel:	  elimina/on	  rate	  
hCp://sepia.unil.ch/pharmacology/index.php?id=71	  








(b) An example of a two-compartment model.
Figure 3.1: Examples of different compartment models.
first-order linear differential equation as shown in Equations 3.1, 3.2 and 3.3.
dC
dt
= kel ·C , (3.1)
Cini t = doseV , at timet = 0, (3.2)
C = dose
V
·e kel ·t , (3.3)
where V denotes the body volume and kel stands for the elimination rate of the drug inside
the body, which generally depends on the liver metabolic capacity or of the renal function
(expressed by creatinine cl arance), depending on the drug.
Furthermore, if we assume that the drug is taken orally, we need to consider one more compo-
nent, i .e. themechanism of absorption from the gastrointestinal (GI) tract to the arteriovenous






3.2. Support Vector Machines
3.4.
C = F ·dose ·ka
V · (ka  kel ) · {e
 kel ·t  e ka ·t }, (3.4)
where ka is the absorption rate and F is an extent factor called bioavailability.
Practically, in real clinical scenarios, since drugs are usually given as series of shots, multiple
dose regimens are more interesting to clinicians. Afterm doses, the drug concentration can
be estimated as in Equation 3.5.
C = F ·dose ·ka
V · (ka  kel ) · {[
1 e m·kel · 
1 e kel ·  ] ·e
 kel ·t   [1 e
 m·ka · 
1 e ka ·  ] ·e
 ka ·t }, (3.5)
where   stands for the dose interval and t stands for the time corresponding to the computed
drug concentration.
When there is no real measurement of drug concentration in blood, the selection of a drug
dose regimen in the traditional clinical approach is based on the population PK parameters or
a priori. The patient’s PK parameters are estimated from the measured drug concentration in
blood without relying in any way on the population model.
The Bayesian approach incorporates the above two models [25]. It first uses the a priori
PK parameters of the population model as the starting estimate for a patient, and then it
adjusts these estimates based on the newmeasured drug concentration values, taking into
consideration the variability of the population parameters. This is known as a posteriori
adaptation aswill be discussed in Section 5.4. Mathematically, it tries tominimize the following








(Ppop j  Pcalc j )2
variance j
, (3.6)
whereCobs andCcalc stand for observed (or measured) drug concentration and calculated
drug concentration respectively, Ppop and Pcalc j are parameter values obtained from a
population study and the estimated parameter values respectively, and N1 is the number of
data points, while N2 denotes the number of patient parameters.
3.2 Support Vector Machines
Unlike the traditional PK approaches as presented above, Support Vector Machines do not
use a specific analytical model but train a model by using a data library which contains
previous patients’ information. SVMs have been widely applied to solve both classification
and regression problems. They are supervised learning models with associated learning
algorithms that analyze data and recognize patterns. They are also one of the most popular
application of kernel methods. Therefore, firstly, Section 3.2.1 introduces the basic idea of the
27
C:	  concentra/on	  value	  
F:	  constant	  factor	  
V:	  body	  volume	  
Ka:	  absorp/on	  rate	  
Kel:	  elimina/on	  rate	  
hCp://sepia.unil.ch/pharmacology/index.php?id=71	  
Two	  compartment	  model	  
32	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▲ A	  mathema7cal	  model	  that	  can	  ‘learn’	  from	  data	  
▲ Advantages	  
▽ Accept	  any	  data	  type	  (con7nuous/discrete)	  
▽ Robust	  in	  various	  domains	  
▲ Limita7on	  
▽ Training	  data	  can	  bias	  the	  model	  
Machine learning approaches 
Training	  data	   Output	  	  
Model	  
Supervised	  learning	  cases	  
Tes7 g	  dat 	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Drug administration decision support system 
(DADSS) 
▲  Train	  the	  SVM	  model	  
based	  on	  previous	  
pa7ents’	  data	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Drug administration decision support system 
(DADSS) 
▲  Train	  the	  SVM	  model	  
based	  on	  previous	  
pa7ents’	  data	  
▲  Compute	  the	  drug-­‐
concentra7on-­‐to-­‐7me	  
curve	  for	  a	  new	  pa7ent	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Drug administration decision support system 
(DADSS) 
▲  Train	  the	  SVM	  model	  
based	  on	  previous	  
pa7ents’	  data	  
▲  Compute	  the	  drug-­‐
concentra7on-­‐to-­‐7me	  
curve	  for	  a	  new	  pa7ent	  
▲  Compare	  concentra7on	  
value	  according	  to	  the	  
therapeu7c	  range	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Drug administration decision support system 
(DADSS) 
▲  Train	  the	  SVM	  model	  
based	  on	  previous	  
pa7ents’	  data	  
▲  Compute	  the	  drug-­‐
concentra7on-­‐to-­‐7me	  
curve	  for	  a	  new	  pa7ent	  
▲  Compare	  concentra7on	  
value	  according	  to	  the	  
therapeu7c	  range	  
▲  Recommend	  dose	  and	  
administra7on	  frequency	  




▲ Verify	  that	  a	  therapeu7cal	  protocol	  is	  
▽ Consistent	  
▽ Complete	  
▲ Verify	  that	  a	  drug	  administra7on	  control	  unit	  
is	  an	  implementa6on	  with	  the	  protocol	  
▽ Model	  checking	  
The verification problem 
40	  
Formal model of Imatinib protocol 
41	  
▲ Reason	  about	  proper7es	  in	  a	  formal	  way	  
▽ Check	  for	  proper7es	  and	  invariants	  
▲ Synthesize	  op7mal	  control	  policies	  for	  drug	  
administra7on	  
▲ Golden	  model	  to	  verify	  hardware	  
implementa7on	  
Advantages of formal models 
42	  
▲ Very	  few	  protocols	  have	  a	  formal	  descrip7on	  
▽ Corner	  cases	  are	  hazardous	  for	  pa7ents	  
▲ Personaliza7on	  of	  drug	  dosage	  is	  important	  
▽ But	  used	  in	  s7ll	  few	  cases	  
▲ Modeling	  human	  body	  reac7on	  is	  cri7cal	  





▲ Electronic	  implants:	  a	  lab	  under	  the	  skin	  
▲ Drug	  monitoring	  and	  administra7on	  
▲ Conclusions	  
44	  





▲ Strong	  need	  to	  generate	  relevant	  data	  (sensors)	  
	  and	  to	  process	  big	  data	  
▲ Strong	  societal	  and	  economic	  push	  
Back to megatrends 
45	  
▲ Health	  care	  of	  elderly	  and	  isolated	  persons	  
▽ Telemedicine	  
▲ Well-­‐being	  of	  ac7ve	  persons	  
▽ Weight	  monitoring	  
▽ Sport	  ac7vity	  monitoring	  
▽ Habits	  
▲ Poten7ally	  large	  market	  for	  selling	  devices,	  
soqware	  and	  services	  
Soft care – healthy individuals 
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▲ E-­‐health	  is	  an	  unstoppable	  life-­‐changing	  trend	  
with	  unlimited	  possibili7es	  
▲ The	  market	  is	  ar7culated:	  
▽ Some	  areas	  are	  harder	  than	  others	  to	  penetrate	  
▽ Many	  problems	  are	  s7ll	  not	  well	  understood	  
▽ Ethics	  and	  regula7ons	  play	  a	  major	  role	  
▲ Exci7ng	  ﬁeld	  for	  researchers	  and	  developers	  
Opportunities and challenges 
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Nano-­‐Tera.ch:	  	  Mission	  
Research, Design & Engineering of complex tera-scale systems 
 using nano-scale devices and technologies  
Main	  applica7on	  domains	  are	  Health	  and	  Environment	  	  
with	  transversal	  themes	  such	  as	  Energy	  and	  Security	  
• 	  	  Develop	  new	  markets	  
• 	  	  Improve	  living	  standards	  
• 	  	  BeCer	  the	  quality	  of	  health	  and	  environment	  
• 	  	  Foster	  a	  vision	  of	  engineering	  with	  social	  objec7ves	  
• 	  	  Promote	  related	  educa7onl	  programs	  
Foster research and crossbreeding of technologies  
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Nano-Tera.ch: key figures 
•  118 projects ( 19+25 RTD large projects) 
•   30 MCHF/year ( approximatively 50% in cash + institutional matching) 
•   36 Swiss research institutions involved (currently)  
•   189 research groups (currently) 
•   ~700 researchers 
•   ~180 PhD thesis supported 
•  ~	  750 papers published 
•  ~	  1300 presentations 
•  37 awards 
•  24 patents 
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Conclusions 
▲ New	  electronic	  health	  systems	  and	  services	  will	  be	  
enabled	  by	  advances	  in	  biology	  and	  medicine	  –	  
combined	  with	  progress	  in	  cyber-­‐physical	  systems	  
▲ The	  ra7onaliza7on	  of	  health	  care	  will	  provide	  
advanced	  care	  to	  a	  broader	  audience	  at	  lower	  cost	  
▲ Human	  factors	  will	  s7ll	  be	  central	  to	  decisions	  in	  
medicine	  	  -­‐	  decision	  support	  will	  be	  automated	  
50	  
Thank you 
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